Acutus Medical to Cancel Third Quarter 2023 Conference Call
Acutus Medical, Inc. (Nasdaq: AFIB) Cancels Q3 Results Conference Call and Webcast After Strategic Realignment and Corporate Restructuring
Negative
Cancellation of Q3 results conference call and webcast may lead to reduced transparency and investor communication.
11/10/2023 - 04:01 PM
CARLSBAD, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), today announced that, following the Company’s announcement of its strategic realignment of resources and corporate restructuring and release of its third quarter results on November 8, 2023, the Company will no longer hold its third quarter results conference call and webcast which was previously scheduled for Monday, November 13, 2023.
About Acutus Medical, Inc.
Investor Contact: Chad Hollister Acutus Medical, Inc. D: 442-232-6080 investors@acutus.com
Why did Acutus Medical, Inc. cancel its Q3 results conference call and webcast?
Acutus canceled the call and webcast following a strategic realignment and corporate restructuring, along with the release of its Q3 results on November 8, 2023.
What is the ticker symbol of Acutus Medical, Inc.?
The ticker symbol for Acutus Medical, Inc. is AFIB.
When was the Q3 results conference call and webcast scheduled to take place?
The call and webcast were previously scheduled for Monday, November 13, 2023.
AFIB Rankings
#4022 Ranked by Stock Gains
AFIB Stock Data
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
Tags
Distribution Services, Medical Distributors, Health Technology, Medical Specialties, Manufacturing, Surgical and Medical Instrument Manufacturing
About AFIB
world class talent with the mission to reshape ep acutus medical has attracted some of the most respected pioneers and leaders in electrophysiology and cardiac device manufacturing to join our organization and our worldwide network of collaborative partners. the common bond that brings us together is our passion and collective capability to revolutionize a field that has not seen major technological advances in decades. our mission of continual innovation is focused on providing electrophysiologists with the highest quality suite of tools, coupled with outstanding clinical and technical support, to better understand and effectively treat complex arrhythmias. electrophysiology is a high growth market with a clear need for a leap-frog technology to address the unmet need for a scientific, medical evidence-based approach to treating atrial fibrillation, ventricular tachycardia and the other complex arrhythmia's. acutus medical is a full-portfolio solution provider for treating these patie
